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We thank Dr Hamburger for the opportunity to revisit the
issue of the safety of Hylan G-F 20 (Synvisc).
As a group of investigators our primary papers published
in 20021,2 as well as the subsequent a posteriori
analyses3e5 were driven by statistical plans and protocols
that carefully deﬁned the variables we would look at as well
as the hypotheses that would drive our analyses and
discussion. Since we were doing many subsequent analy-
ses than were originally planned in the primary protocol, we
felt that we had to be very stringent in describing how we use
the alpha values that would declare a P value statistically
signiﬁcant. In our case3, we chose to be explicit with how we
used the Bonferroni adjustment to prevent these secondary
analyses from dominating the primary purpose of the study.
Dr Hamburger has chosen to interpret the ﬁndings with the
conventional level of signiﬁcance, namely the 5% level. As
a reader of our work he is free to choose his own level of
signiﬁcance for his interpretation. We simply disagree with
his choice of the level criterion. To our knowledge, our study
is the only published report in which hypotheses were
generated and tested systematically to establish the efﬁcacy
and safety of repeat exposure to a viscosupplement (Hylan
G-F 20), using data from a large multicentered, randomized
clinical trial.
Dr Hamburger claims we failed to consider the work that
he and others have published long after we designed and
analyzed our data. We conducted a pragmatic study so did
not require the clinicians to do all the measurements on
reasons for arthrocentesis as well as any other side effects
claimed by Dr Hamburger. Indeed, we did not even have
the clinicians agree as to what they would call an
arthrocentesis, and so we are not certain as to their
reliability of scoring and meaning. Moreover, acute pain and
swelling of the knee may in fact be an aggravation of the
underlying disease itself, including effusion that warrants
aspiration and not necessarily related to a local reaction to
intra-articular injections of the viscosupplement.
We did not ask for additional measures that would have
permitted a differential diagnosis. Since this was not part of
our protocol, we cannot be accused of ‘‘failing to do’’ so
when the papers being cited were two in 2002, and one
each in 2004 and 2005. Finally, our protocol did not specify
that any adverse reactions would be combined in a meta-
analysis with the other reports in the literature. Most of Dr
Hamburger’s information on local adverse events are drawn
from case reports, reviews of case reports, excerpts from
trials, and similar observational data. Indeed, we are not
sure how one would properly combine case reports, case
series, database cohorts and randomized trials to provide
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certainly not the precise numerical estimates.
Dr Hamburger seems to have confused how we chose to
report our data. We chose to report rates of events that he
claims are incidence rates. This is incorrect since an
incidence rate is the conversion of a patient from non-
disease to disease over a speciﬁc time frame, so his use of
the word ‘‘incidence’’ should always be a rate, because the
time frame has not been stated at any point in his letter.
Finally, taking rates for rabbits and other primates without
doing similar measures in humans can give clues as to
possible causes, but certainly does not provide evidence of
a human mechanism unless it has been similarly measured
in humans. Many of Dr Hamburger’s suggestions that he
leveled as criticisms of our work could be the focus of head
to head studies of the various hyaluronic products to see if
the claims that Hylan G-F 20 is different from the rest is
indeed born out in humans. Such studies do not appear to
have been done to make the claims that Dr Hamburger is
making in his letter. While we agree such studies would be
clinically valuable, drawing the conclusion that Hylan G-F
20 is worse in multiple course therapy and different from
other hyaluronic products seems to be a premature
conclusion.
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